Circumvention Of Tumor Cell Escape Following Specific Immunotherapy
- 1 April 2000
- journal article
- review article
- Published by Mary Ann Liebert Inc in Cancer Biotherapy & Radiopharmaceuticals
- Vol. 15 (2) , 141-152
- https://doi.org/10.1089/cbr.2000.15.141
Abstract
The development of tumor cell resistance to chemotherapy has led to the potential application of immuno-gene therapy in the treatment of drug resistant tumors. However, tumor cells develop cross-resistance to immunotherapy and resistance to immune-mediated apoptotic mechanisms. Therefore, imunosensitization of tumor cells is required to overcome their resistance to immunotherapy.Keywords
This publication has 45 references indexed in Scilit:
- Apoptosis: Telling cells their time is upCurrent Biology, 1996
- Molecular Mechanisms of Lymphocyte-Mediated Cytotoxicity and Their Role in Immunological Protection and Pathogenesis In VivoAnnual Review of Immunology, 1996
- Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinial relevanceImmunology Today, 1995
- A role for CD95 ligand in preventing graft rejectionNature, 1995
- Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)Nature, 1995
- Fas and Perforin Pathways as Major Mechanisms of T Cell-Mediated CytotoxicityScience, 1994
- Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor familyCell, 1993
- Natural history of HLA expression during tumour developmentImmunology Today, 1993
- Involvement of TNF-α mRNA downregulation in tumor cell sensitivity to TNF-α Pentoxifylline enhances sensitivity of a human ovarian cancer cell line (OVC-8) to TNF-αBiotherapy, 1993
- Cycloheximide-induced modulation of TNF-mediated cytotoxicity in sensitive and resistant ovarian tumor cellsCancer Chemotherapy and Pharmacology, 1990